0001209191-22-053703.txt : 20221014 0001209191-22-053703.hdr.sgml : 20221014 20221014184616 ACCESSION NUMBER: 0001209191-22-053703 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220826 FILED AS OF DATE: 20221014 DATE AS OF CHANGE: 20221014 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hirano Patricia C CENTRAL INDEX KEY: 0001766042 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36593 FILM NUMBER: 221312298 MAIL ADDRESS: STREET 1: 1235 RADIO ROAD STREET 2: SUITE 110 CITY: REDWOOD CITY STATE: CA ZIP: 94065 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SOLENO THERAPEUTICS INC CENTRAL INDEX KEY: 0001484565 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 770523891 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 203 REDWOOD SHORES PARKWAY STREET 2: SUITE 500 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-213-8444 MAIL ADDRESS: STREET 1: 203 REDWOOD SHORES PARKWAY STREET 2: SUITE 500 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: Capnia, Inc. DATE OF NAME CHANGE: 20100219 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-08-26 0 0001484565 SOLENO THERAPEUTICS INC SLNO 0001766042 Hirano Patricia C 203 REDWOOD SHORES PKWY, STE 500 REDWOOD CITY CA 94065 0 1 0 0 See Remarks Common Stock 9273 D Employee stock option (right to buy) 44.25 2027-04-19 Common Stock 266 266 D Employee stock option (right to buy) 24.00 2028-02-07 Common Stock 6000 6000 D Employee stock option (right to buy) 25.05 2029-01-24 Common Stock 4400 4400 D Employee stock option (right to buy) 51.15 2030-05-18 Common Stock 2333 2333 D Employee stock option (right to buy) 33.60 2031-01-08 Common Stock 21533 21533 D Employee stock option (right to buy) 5.10 2032-01-28 Common Stock 7333 7333 D Employee stock option (right to buy) 2.595 2032-07-27 Common Stock 13333 13333 D Warrant (right to buy) 4.50 2022-03-31 2027-03-31 Common Stock 1333 1333 D The number of shares beneficially owned reflects the 1-for-15 reverse stock split effected August 26, 2022. Certain of these securities are restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Class A Common Stock, subject to the applicable vesting schedule and conditions of each RSU. The per share exercise price and number of shares subject to the option reflect the 1-for-5 reverse stock split effected October 15, 2017 and the 1-for-15 reverse stock split effected August 26, 2022. All of the shares subject to this option are fully vested and exercisable as of the date hereof. The per share exercise price and number of shares subject to the option reflect the 1-for-15 reverse stock split effected August 26, 2022. One forty-eighth (1/48) of the shares subject to the Option shall vest on the first month anniversary of January 24, 2019 (the "Vesting Commencement Date") and one forty-eighth (1/48) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date. One forty-eighth (1/48) of the shares subject to the Option shall vest on the first month anniversary of May 18, 2020 (the "Vesting Commencement Date") and one forty-eighth (1/48) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date, such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date. Twelve and one-half percent (12.5%) of the shares subject to the Option shall vest upon the date following the acceptance by the US FDA of an NDA submission for DCCR, twelve and one-half percent (12.5%) of the shares subject to the Option shall vest upon the submission by the Company to the European Medicines Agency European of an MAA for DCCR, and one forty-eighth (1/48th) of the remaining shares subject to the Option shall vest each month anniversary of January 8, 2021 (the "Vesting Commencement Date") on the same day of the month as the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date. One forty-eighth (1/48th) of the shares subject to the Option shall vest on the first month anniversary of January 1, 2022 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the total number of shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), such that all of the shares subject to the Option will have vested as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person continuing to be a Service Provider through each such date. One fourth of the shares subject to the option shall vest on August 1, 2022 and each three-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date. The per share exercise price and number of shares subject to the warrant reflect the 1-for-15 reverse stock split effected August 26, 2022. Officer title: Vice President, Regulatory Affairs /s/ Anish Bhatnagar, Attorney-in-Fact 2022-10-14